Last reviewed · How we verify
Buscopan (scopolamine butylbromide)
At a glance
| Generic name | scopolamine butylbromide |
|---|---|
| Drug class | butylscopolamine |
| Target | Muscarinic acetylcholine receptor M1 |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Gastric spasm
Common side effects
- Transient tachycardia
- Decreased borborygmal sounds
- Transient pupillary dilation
Key clinical trials
- Valethamate Bromide Versus Hyoscine Butyl Bromide in Reducing Labour Duration Among Primigravida (NA)
- A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects (PHASE1)
- Representation of Spatiotemporal Information in Human Episodic Memory and Navigation (EARLY_PHASE1)
- Oral Hyoscine vs. Topical EMLA vs. Placebo for Pain Reduction During Hysterosalpingography (NA)
- Evaluation of the Efficacy of the Injection of Botulinum Toxin A vs Scopolamine Patches in the Treatment of Drooling in Children With Cerebral Palsy (PHASE3)
- A Clinical Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Capsules for Preoperative Preparation in Painless Gastrointestinal Endoscopy Procedures (NA)
- Tiotropium vs. Inhaled Corticosteroids in Children With Nonatopic Asthma Pilot Study (TioNAAP) (PHASE2)
- Two-period 21 Day Cross-over Study to Compare the Pharmacokinetics of Tiotropium From Two Inhalers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Buscopan CI brief — competitive landscape report
- Buscopan updates RSS · CI watch RSS
- portfolio CI